The significant efficacy of second-generation anti-HER2 ADCs in the metastatic setting will probably lead to their use in the near future for the treatment of early-stage breast cancer (eBC) as an adjunct to, or in replacement of conventional chemotherapy. Here, ERBB2 is linked to breast carcinoma.